| Patients receiving haemopoietic stem cell transplantation |
| Pt |
Age/sex |
Diagnosis |
Transplantation type |
Conditioning regimen |
| 1 |
60/F |
MM IgAk |
Autolougus |
Melphalan 200 mg/mq |
| 2 |
53/F |
Mantle cell lymphoma |
Autolougus |
Melphalan 200 mg/mq |
| 3 |
65/F |
MM IgG lambda |
Autolougus |
Melphalan 200 mg/mq |
| 4 |
50/M |
MM IgG lambda |
Autolougus |
Melphalan 200 mg/mq |
| 5 |
61/M |
ALL Ph'+ |
Autolougus |
Etoposide 75 mg/mq + 6-mercaptopurine 150 mg/mq |
| 6 |
62/F |
MM IgAk |
Autolougus |
Melphalan 200 mg/mq |
| 7 |
34/M |
AML |
Allogeneic |
Cyclophosphamide + TBI 1200 cGy |
| 8 |
25/F |
ALL |
Allogeneic |
Cyclophosphamide + Thiotepa |
| 9 |
46/M |
Mycosis Fungoides |
RIC allogeneic |
Pentostatin + TBI 2 Gy |
| 10 |
46/M |
Mycosis Fungoides |
RIC allogeneic |
Pentostatin + TBI 2 Gy |
| Patients receiving chemotherapy |
| Pt |
Age/sex |
Diagnosis |
Treatment |
| 11 |
59/F |
B-CLL |
Chlorambucil + FCR |
| 12 |
54/M |
AML |
“MICE” scheme |
| 13 |
25/F |
ALL |
“McMaster” scheme |
| 14 |
59/M |
AML |
“FLANG” scheme |
| 15 |
48/M |
ALL |
“SPLIT” scheme |
|
| MM: Multiple Myeloma; AML: Acute Myeloid Leukemia; ALL: Acute Lymphoblastic Leukemia; B-CLL: B-Chronic Lymphocitic Leukemia; TBI: Total Body Irradiation; MICE: Mitoxantrone-Idarubicin-Cytarabine-Etoposide; FLANG: Fludarabine-Cytarabine-Mitoxantrone; SPLIT: Idarubicin-Cytarabine-Vincristine-Prednisone; RIC: Reduced Intensity Conditioning; FCR: Fludarabine-Cyclophosphamide-Rituximab |
| Table 1: Patien’s characteristics and therapies received. |
